Lipoic acid choline ester

Drug Profile

Lipoic acid choline ester

Alternative Names: EV-06; Thioctic acid choline ester; UNR 844

Latest Information Update: 27 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Encore Vision
  • Developer Novartis
  • Class Carboxylic acids; Coenzymes; Eye disorder therapies; Fatty acids; Thiophenes
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Presbyopia

Most Recent Events

  • 03 Apr 2017 Novartis intends to submit NDA to the US FDA for Presbyopia in 2021
  • 20 Jan 2017 Encore Vision has been acquired and merged into Novartis
  • 05 May 2016 Efficacy and adverse event data from a phase I/II trial in Presbyopia released by Encore Vision
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top